MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.semarthrit.2025.152735

Медицинская библиотека · Seminars in arthritis and rheumatism · 2025

Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: A propensity score-matched, active-comparator, new-user study.

Frideres Halie, Wichman Christopher S, Dong Jianghu, Roul Punyasha, Yang Yangyuna, Baker Joshua F, George Michael D, Johnson Tate M, Rojas Jorge, Sauer Brian C, Cannon Grant W, Matson Scott M, Curtis Jeffrey R, Mikuls Ted R, England Bryant R

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

This study aimed to compare treatment outcomes in rheumatoid arthritis-associated interstitial lung disease (RA-ILD) between initiators of rituximab, abatacept, tocilizumab, and tofacitinib using the Target Trial Emulation Framework.

METHODS

We emulated three trials comparing abatacept, tocilizumab, and tofacitinib with rituximab (reference). Patients fulfilling validated RA-ILD algorithms initiating one of these non-TNFi b/tsDMARDs were propensity score (PS)-matched (1:1) using national Veterans Affairs (VA) data from 2006 to 2020. PS models included demographics, comorbidities, general health status indicators, and several RA- and ILD-related severity measures. Composite study outcomes were death and respiratory-related hospitalization, ascertained by VA data and linkages to the National Death Index and Medicare, over three-year (primary) and one-year follow-up periods (secondary). Cox regression models were used to analyze study outcomes adjusting for any unbalanced variables. Several sensitivity and subgroup analyses were performed.

RESULTS

In the primary cohort, we 1:1 matched abatacept (n = 150), tocilizumab (n = 73), and tofacitinib (n = 94) with equal numbers of rituximab initiators (mean age 68.1-69.4 years, 88-92 % male). There were no significant differences in the primary composite outcome among any of the comparisons (abatacept aHR: 1.03 [0.72, 1.47]; tocilizumab aHR: 1.15 [0.68, 1.93]; tofacitinib aHR: 0.89 [0.54, 1.46]). Secondary, subgroup, and sensitivity analyses supported the main findings.

CONCLUSIONS

We did not find significant differences in mortality or respiratory hospitalization between RA-ILD patients initiating different non-TNFi b/tsDMARDs, though estimates were imprecise, and residual confounding may be present. These findings emphasize the need for clinical trials of advanced immunomodulatory therapies in RA-ILD.

Для цитирования: Frideres Halie, Wichman Christopher S, Dong Jianghu, Roul Punyasha, Yang Yangyuna, Baker Joshua F, George Michael D, Johnson Tate M, Rojas Jorge, Sauer Brian C, Cannon Grant W, Matson Scott M, Curtis Jeffrey R, Mikuls Ted R, England Bryant R. Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: A propensity score-matched, active-comparator, new-user study.. Seminars in arthritis and rheumatism. 2025. DOI: 10.1016/j.semarthrit.2025.152735.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.